

# INTERNATIONAL SEARCH REPORT

In  International Application No  
PCT/DK2004/000242

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07J3/00 C07J31/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category <sup>a</sup>	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97/24365 A (GLAXO GROUP LTD ; BIGGADIKE KEITH (GB); PROCOPIOU PANAYIOTIS ALEXANDER) . 10 July 1997 (1997-07-10) page 11, line 25 - page 13, line 6	1-22
X	WO 02/08243 A (COOTE STEVEN JOHN ; ROBINSON JOHN MALCOLM (GB); GLAXO GROUP LTD (GB) 31 January 2002 (2002-01-31) page 6, lines 1-15	1-16
X	GB 2 088 877 A (GLAXO GROUP LTD) 16 June 1982 (1982-06-16) page 3, line 51 - page 5, line 29	1-22
X	US 4 578 221 A (BAIN BRIAN M ET AL) 25 March 1986 (1986-03-25) examples 1-13 claims 1,7	1-16
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the International search

3 August 2004

Date of mailing of the International search report

18/08/2004

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 51 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Samsam Bakhtiary, M

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/DK2004/000242

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/12265 A (COOTE STEVEN JOHN ; BIGGADIKE KEITH (GB); GLAXO GROUP LTD (GB); NICE R) 14 February 2002 (2002-02-14) page 21, line 1 - page 22, line 25	1-16
X	HAPGOOD, JANET P. ET AL: "Steroid-affinity purification of the rat liver glucocorticoid hormone receptor complex" JOURNAL OF STEROID BIOCHEMISTRY ( 1987 ), 28(6), 769-77 CODEN: JSTBBK; ISSN: 0022-4731, 1987, XP001183044 page 770, right-hand column, paragraph 2	17,18
X	HOYTE, R. M. ET AL: "Synthesis and evaluation of potential radioligands for the progesterone receptor" JOURNAL OF MEDICINAL CHEMISTRY ( 1985 ), 28(11), 1695-9 CODEN: JMCMAR; ISSN: 0022-2623, 1985, XP001182782 page 1696, right-hand column; compound 15	17,18
X	MACINDOE, JOHN H. ET AL: "Comparative studies of 5.alpha.-reductase inhibitors within MCF-7 human breast cancer cells" JOURNAL OF STEROID BIOCHEMISTRY ( 1984 ), 20(5), 1095-100 CODEN: JSTBBK; ISSN: 0022-4731, 1984, XP001182781 page 1096, left-hand column, last paragraph - page 1096, right-hand column, line 11	17,18
X	FORMSTECHER, P. ET AL: "Synthesis of steroidal 17.beta.-carboxamide derivatives" STEROIDS ( 1980 ), 35(3), 265-72 CODEN: STEDAM; ISSN: 0039-128X, 1980, XP001182780 page 266 formula III	17-19
X	KOLBE, ADELHEID ET AL: "Syntheses of dexamethasone conjugates of the phytohormones gibberellin A3 and 24-epicastasterone" COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS ( 2002 ), 67(1), 103-114 CODEN: CCCCAK; ISSN: 0010-0765, 2002, XP001194682 page 104; compound 3	17-19
		-/-

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/DK2004/000242

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HEUBNER, ARNULF ET AL: "Application of liquid-liquid partition chromatography in the simultaneous purification of sex-hormone-binding globulin and corticosteroid-binding globulin" JOURNAL OF CHROMATOGRAPHY ( 1987 ), 397, 419-34 CODEN: JOCRAM; ISSN: 0021-9673, 1987, XP001194688 page 420, paragraph 4	17-19
X	PHILLIPPS G H ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF ANTIINFLAMMATORY CORTICOSTEROID ANALOGUES, HALOMETHYL ANDROSTANE-17BETA-CARBOTHIOATES AND-17BETA-CARBOSELENOATES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 37, no. 22, 1 October 1994 (1994-10-01), pages 3717-3729, XP002025925 ISSN: 0022-2623 cited in the application page 3718 scheme 3	1-16
X	MANZ, BERNHARD ET AL: "Synthesis of biotin-labeled dexamethasone derivatives. Novel hormone-affinity probes" EUROPEAN JOURNAL OF BIOCHEMISTRY ( 1983 ), 131(2), 333-8 CODEN: EJBCAI; ISSN: 0014-2956, 1983, XP009034828 page 334; figure 1	17-19
X	GOVINDAN, MANJAPRA V. ET AL: "Three-step purification of glucocorticoid receptors from rat liver" EUROPEAN JOURNAL OF BIOCHEMISTRY ( 1980 ), 108(1), 47-54 CODEN: EJBCAI; ISSN: 0014-2956, 1980, XP009034821 page 47, right-hand column, last paragraph	17-19

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No  
PCT/DK2004/000242

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9724365	A	10-07-1997	AT 194356 T AU 721865 B2 AU 1140997 A BG 102625 A BR 9612309 A CA 2241728 A1 CN 1209135 A ,B CZ 9802074 A3 DE 69609199 D1 DE 69609199 T2 DK 876392 T3 EA 1401 B1 EE 9800227 A EP 0876392 A1 ES 2150150 T3 WO 9724365 A1 GR 3034564 T3 HK 1012193 A1 HU 9903707 A2 JP 2947944 B2 JP 11501675 T NO 983004 A NZ 324373 A OA 10701 A PL 327629 A1 PT 876392 T SI 876392 T1 SK 89198 A3 TR 9801247 T2 TW 498072 B US 6197761 B1	15-07-2000 13-07-2000 28-07-1997 30-04-1999 13-07-1999 10-07-1997 24-02-1999 11-11-1998 10-08-2000 01-03-2001 06-11-2000 26-02-2001 15-12-1998 11-11-1998 16-11-2000 10-07-1997 31-01-2001 23-01-2001 28-03-2000 13-09-1999 09-02-1999 26-08-1998 28-10-1999 21-05-2002 21-12-1998 29-12-2000 31-12-2000 10-03-1999 23-11-1998 11-08-2002 06-03-2001
WO 0208243	A	31-01-2002	AU 7090601 A BR 0110430 A CA 2406963 A1 CN 1437610 T CZ 20023472 A3 EP 1301526 A1 WO 0208243 A1 HU 0301108 A2 JP 2004504403 T NO 20025054 A NZ 522083 A US 2004043974 A1	05-02-2002 08-07-2003 31-01-2002 20-08-2003 16-04-2003 16-04-2003 31-01-2002 28-08-2003 12-02-2004 05-11-2002 25-06-2004 04-03-2004
GB 2088877	A	16-06-1982	CY 1291 A AT 395428 B AT 17084 A AT 401521 B AT 34491 A AT 395427 B AT 67481 A AT 395429 B AT 203186 A AU 544517 B2 AU 6729881 A BE 887518 A1 BG 60700 B2	18-10-1985 28-12-1992 15-05-1992 25-09-1996 15-02-1996 28-12-1992 15-05-1992 28-12-1992 15-05-1992 06-06-1985 20-08-1981 13-08-1981 29-12-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No  
PCT/DK2004/000242

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
GB 2088877	A	CA	1201114 A1	25-02-1986	
		CA	1205464 A2	03-06-1986	
		CH	644615 A5	15-08-1984	
		CH	651307 A5	13-09-1985	
		CZ	9104034 A3	16-03-1994	
		DE	3105307 A1	10-12-1981	
		DE	3153379 C2	19-11-1992	
		DK	62381 A ,B,	16-08-1981	
		ES	8207194 A1	01-12-1982	
		ES	8305379 A1	01-07-1983	
		ES	8402317 A1	16-04-1984	
		ES	8502447 A1	01-04-1985	
		ES	8600936 A1	16-02-1986	
		FI	810444 A ,B,	16-08-1981	
		FR	2477156 A1	04-09-1981	
		FR	2485542 A1	31-12-1981	
		GB	2137206 A ,B	03-10-1984	
		HK	58385 A	16-08-1985	
		IE	51394 B1	24-12-1986	
		IE	51395 B1	24-12-1986	
		IT	1170717 B	03-06-1987	
		JP	1488353 C	23-03-1989	
		JP	56138200 A	28-10-1981	
		JP	63037120 B	22-07-1988	
		KE	3526 A	07-06-1985	
		KR	8500969 B1	02-07-1985	
		MX	9202717 A1	30-06-1992	
		MY	75785 A	31-12-1985	
		NL	84649 C		
		NL	960029 I1	03-02-1997	
		NL	8100707 A ,B,	16-09-1981	
		NZ	196260 A	30-11-1983	
		PH	24267 A	29-05-1990	
		PT	72502 A ,B	01-03-1981	
		SE	452468 B	30-11-1987	
		SE	8101010 A	16-08-1981	
		SG	36885 G	15-11-1985	
US 4578221	A	25-03-1986	AT	395428 B	28-12-1992
			AT	17084 A	15-05-1992
			AT	401521 B	25-09-1996
			AT	34491 A	15-02-1996
			AT	395427 B	28-12-1992
			AT	67481 A	15-05-1992
			AT	395429 B	28-12-1992
			AT	203186 A	15-05-1992
			AU	544517 B2	06-06-1985
			AU	6729881 A	20-08-1981
			BG	60700 B2	29-12-1995
			CH	644615 A5	15-08-1984
			CH	651307 A5	13-09-1985
			CZ	9104034 A3	16-03-1994
			DE	3105307 A1	10-12-1981
			DE	3153379 C2	19-11-1992
			DK	62381 A ,B,	16-08-1981
			ES	8207194 A1	01-12-1982
			ES	8305379 A1	01-07-1983
			ES	8402317 A1	16-04-1984

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l	Application No
	PCT/DK2004/000242

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4578221	A	ES	8502447 A1	01-04-1985
		ES	8600936 A1	16-02-1986
		FI	810444 A ,B,	16-08-1981
		FR	2477156 A1	04-09-1981
		FR	2485542 A1	31-12-1981
		GB	2137206 A ,B	03-10-1984
		HK	58385 A	16-08-1985
		IE	51394 B1	24-12-1986
		IE	51395 B1	24-12-1986
		IT	1170717 B	03-06-1987
		KE	3526 A	07-06-1985
		KR	8500969 B1	02-07-1985
		MX	9202717 A1	30-06-1992
		MY	75785 A	31-12-1985
		NL	84649 C	
		NL	960029 I1	03-02-1997
		NL	8100707 A ,B,	16-09-1981
		NZ	196260 A	30-11-1983
		PT	72502 A ,B	01-03-1981
		SE	452468 B	30-11-1987
		SE	8101010 A	16-08-1981
		SG	36885 G	15-11-1985
		SK	403491 A3	07-02-1996
		US	2794508 A	04-06-1957
		US	4650610 A	17-03-1987
WO 0212265	A 14-02-2002	AU	7576001 A	18-02-2002
		AU	7649701 A	18-02-2002
		BG	107518 A	30-09-2003
		BR	0113039 A	15-07-2003
		BR	0113042 A	08-07-2003
		CA	2417825 A1	14-02-2002
		CA	2417826 A1	14-02-2002
		CN	1468252 T	14-01-2004
		CN	1468253 T	14-01-2004
		CZ	20030353 A3	14-05-2003
		EP	1305329 A1	02-05-2003
		EP	1305330 A1	02-05-2003
		WO	0212265 A1	14-02-2002
		WO	0212266 A1	14-02-2002
		HU	0303084 A2	29-12-2003
		HU	0303354 A2	28-01-2004
		JP	2004505989 T	26-02-2004
		JP	2004505990 T	26-02-2004
		MA	25899 A1	01-10-2003
		NO	20030549 A	04-02-2003
		NO	20030550 A	04-04-2003
		SK	1422003 A3	03-06-2003
		US	2002177581 A1	28-11-2002
		US	2003073676 A1	17-04-2003
		US	2002173496 A1	21-11-2002
		US	2003153542 A1	14-08-2003
		US	2002165211 A1	07-11-2002
		US	2003109511 A1	12-06-2003
		US	2004028615 A1	12-02-2004
		US	2003199485 A1	23-10-2003
		US	2003045512 A1	06-03-2003
		US	2003092690 A1	15-05-2003

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

**PCT**

**NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT AND  
THE WRITTEN OPINION OF THE INTERNATIONAL  
SEARCHING AUTHORITY, OR THE DECLARATION**

(PCT Rule 44.1)

<b>To:</b> <b>ALPHARMA APS</b> <b>Dalslandsgræde 3,1</b> <b>DK-2300 Copenhagen S</b> <b>DENMARK</b>	<b>Date of mailing (day/month/year)</b> <b>18/08/2004</b>
<b>Applicant's or agent's file reference</b> <b>2003-100 PC</b>	<b>FOR FURTHER ACTION</b> See paragraphs 1 and 4 below
<b>International application No.</b> <b>PCT/DK2004/000242</b>	<b>International filing date (day/month/year)</b> <b>02/04/2004</b>
<b>Applicant</b>  <b>ALPHARMA APS</b>	

1.  The applicant is hereby notified that the International search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmission of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO, 34 chemin des Colombettes  
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2.  The applicant is hereby notified that no International search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

3.  With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

- the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
- no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Reminders

Shortly after the expiration of 18 months from the priority date, the International application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 18 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.


In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 18 months.

See the Annex to Form PCT/I/8/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

<b>Name and mailing address of the International Searching Authority</b>  <b>European Patent Office, P.O. Box 5018 Patentsteen 2</b> <b>NL-2280 HV Rijswijk</b> <b>Tel. (+31-70) 340-2040, Fax: 31 651 000 nl,</b> <b>Fax: (+31-70) 340-3016</b>	<b>Authorized officer</b> <b>Josef Ullrich</b>
--	---

**CLAIMS**

1. A method for preparing a steroidal carbothioic acid or a salt thereof, said method comprises:  
A) reacting a steroidal carboxylic acid or a salt thereof with a coupling agent selected from the  
5 group consisting of carbodiimide derivatives represented by the following formula:



wherein R<sub>a</sub> and R<sub>b</sub> are the same or different, and each represent an aliphatic, heteroaliphatic, carbocyclic or a heterocyclic group [all said groups are optionally substituted]; alone or in conjunction with a coupling enhancer; and


10. B) reacting the product of step A) with a nucleophilic agent comprising a sulfur atom.

**2. A method according to claim 1 in which the coupling agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).**


15. 3. A method according to claim 2, in which the coupling agent is the hydrochloride salt of EDC.

4. A method according to any of the preceding claims, in which the coupling enhancer is selected from the group consisting of:

A) a heterocyclic ring containing one or two nitrogen atoms, said ring being optionally substituted; such as a compound of formula (D) or formula (E),



wherein R<sub>11</sub> and R<sub>12</sub> can be the same or different, and each represent a hydrogen atom or a cyano group; R<sub>13</sub> represent a hydrogen atom or an alkyl group; and R<sub>14</sub> represent a hydrogen atom or a salt of a sulfonic acid such as sodium sulfonate [-S(=O)(=O)-O<sup>-</sup>Na<sup>+</sup>]; and  
 B) an unsaturated 5-6 membered heterocyclic ring fused to an aromatic- or heteroaromatic ring  
 In which the said heterocyclic ring contains three nitrogen atoms, said rings being optionally substituted, such as a compound of formula (F) or formula (G),



$X = H, F, Cl, Br$  and  $Y = CH, N, O, S$

**AMENDED SHEET**

preferably 6-chloro-hydroxybenzotriazole (6-Cl-HOBt), 7-aza-hydroxybenzotriazole (HOAt), or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (Obht-OH).

5. A method according to any of the preceding claims, where the nucleophilic agent comprising a sulfur atom is selected from the group comprising:


- compounds of formula  $[M]^+ [SH]^-$  wherein M is a metal such as Li, Na or K; or  $[M]^{2+} [S]^{2-}$  wherein M is a metal such as Ca or Mg, the said sulfide salts being optionally hydrated (such as sodium hydrosulfide hydrate); and

10 - an *in situ* generated sulfide salt or a hydrated sulfide salt.

6. The method of any of the preceding claims, wherein the nucleophilic agent is dissolved in a suitable solvent prior to addition to the reaction mixture, or wherein the nucleophilic agent is added in the form of a solid salt or as a solution of the salt in water and/or an organic solvent or  
15 a combination thereof.

7. A method according to any of the preceding claims for preparing a steroidal carbothioic acid of formula (IV) or a salt thereof

20



Wherein the symbol  $\equiv$  in the 1,2-position represent a single or a carbon-carbon double bond;

25  $R_1$  represents a hydrogen atom, a hydroxy- or an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, a group  $-O-C(=O)-R_6$ , where  $R_6$  is an alkyl group (such as optionally substituted  $C_{1-6}$  alkyl) or an optionally substituted 5-6 membered heterocyclic ring containing either oxygen, nitrogen or sulfur as ring hetero atom (such as a furanyl-, pyrrolyl- or a thiophenyl group);

30  $R_2$  represents a hydrogen atom, a hydroxy group, an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, an alkyl group (such as an optionally substituted  $C_{1-6}$  alkyl) which may be in either the  $\alpha$ - or  $\beta$ -configuration, an alkylene group (such as an optionally substituted  $C_{1-6}$  alkylene having the two free valencies on the same carbon atom,


2 AMENDED SHEET

6-Dec. 2004 18:52

Nr. 0454 S. 9

2003-100 PC

preferably methylene) [the alkylene group bound to the steroid nucleus via a double bond] or R<sub>1</sub> and R<sub>2</sub> together represent



5 where R<sub>7</sub> and R<sub>8</sub> are the same or different and each represent a hydrogen atom or an alkyl group (such as an optionally substituted C<sub>1-6</sub> alkyl);

R<sub>3</sub> represent a hydrogen atom, hydroxy- or a protected hydroxy group in either the α- or β- configuration or an oxo group (in which case the bond between R<sub>3</sub> and the steroid nucleus is a double bond);


10 R<sub>4</sub> represents a hydrogen- or a halogen atom or R<sub>3</sub> and R<sub>4</sub> together represent a carbon-carbon bond or an epoxy group in the β-configuration; and

R<sub>5</sub> represents a hydrogen- or a halogen atom in either the α- or β-configuration;

R<sub>9</sub> represents a hydrogen atom or R<sub>9</sub> represent a metal ion [eg. the moiety -S-R<sub>9</sub> represents a group of the formula [-S][M]<sup>+</sup> wherein M is a metal such as Li, Na or K]; the method

15 comprising;

A) reacting a steroidal carboxylic acid of formula (II) or a salt thereof



20 in which the substituents of formula (II) have the above defined meaning with a coupling agent alone or in conjunction with an coupling enhancer, followed by the reaction with a nucleophilic agent comprising a sulfur atom; and optionally

B) reacting the product from step A) with an acid.

25 8. The method of any of the preceding claims, wherein i)

- the coupling agent is added before the coupling enhancer, or
- the coupling enhancer is added before the coupling agent, and/or wherein ii)
- the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer, or wherein

30 - a mixture of the coupling agent and the coupling enhancer is added to a steroidal carboxylic acid, or wherein

### 3 AMENDED SHEET

6. Dec. 2004 18:52

Nr. D454 S. 10


2003-100 PC

- the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer in a polar aprotic solvent, preferably DMF or DMA, at elevated temperature.

5 9. A method for preparing a steroidal carbothioate (i.e. the ester of the steroidal carbothioic acid), or a salt thereof, the method comprising;  
reacting a steroidal carbothioic acid or a salt thereof, which is prepared as defined in any of the preceding claims, with an electrophilic agent.


10 10. A method according to claim 9, in which the electrophilic agent is selected from the group consisting of: C<sub>1-6</sub> di- or trihaloalkanes, preferably a trihalo- or a dihalomethane, such as chlorobromomethane or bromofluoromethane.

11. A method according to claim 9 or 10 for preparing a steroidal carbothioate of formula (I)  
15



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are defined as in claim 7; and  
R<sub>10</sub> represents a C<sub>1-6</sub> haloalkyl or an optionally substituted heterocyclic ring, the method comprising:

20 A) reacting a steroidal carboxylic acid of formula (II)




with a coupling agent and a coupling enhancer [such as a compound of formula (D) or formula (E)]

25

4

SEARCHED SHEET



wherein R<sub>11</sub> and R<sub>12</sub> independently represent a hydrogen atom or a cyano group (C≡N);


$R_{13}$  represent a hydrogen atom or an alkyl group; and

5 R<sub>14</sub> represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate (eg. the group -S(=O)(=O)-O Na<sup>+</sup>);

B) reacting the product from step A) with a nucleophilic agent comprising sulfur; and

C) reacting the product from step B) with an electrophilic agent [such as a C<sub>1-6</sub> di- or trihaloalkane, preferably a trihalo- or a dihalomethane such as chlorofluoromethane]

10 bromofluoromethane] or a compound of the following formula;



wherein X=H, F, Cl, Br and; Y=CH<sub>2</sub>, NH, O, S, preferably X=Cl and Y=O.

15

12. The method of claim 11, wherein the coupling enhancer is selected from the group

consisting of: NMI (N-methylimidazole); PCI (4,5-dicyanimidazole); NHS (N-

hydroxysuccinimide); and sulfo-NHS (*N*-hydroxysulfosuccinimide).

20 13. The method of any of the claims 11-12, wherein step C) constitutes the *in situ* reaction of  
the product from step B) with bromofluoromethane to form a compound of formula (I) wherein  
 $R_{11}$  is a fluoromethyl group, such as fluticasone propionate.


14. The method according to any of the preceding claims, in which

25 - at least two subsequent steps are performed *in situ*, i.e. without any change or removal of solvents, or isolation of the individual intermediates; and/or  
- the method is conducted as a continuous method; and/or  
- step A), B) and optionally step C) are conducted as a one-pot synthesis without solvent changes and/or are performed at room or elevated temperature.

15. The method of any of the claims 9-14, wherein an androstane 17 $\beta$ -carboxylic acid is converted to an androstane 17 $\alpha$ -carboethioate.


16. The method of any of the preceding claims, wherein step B) provides an alkali metal salt of  
35 the thioic acid, such as a compound of formula (IV), in which the moiety -S-R<sub>3</sub> represent a

group of the formula  $[-S][M]^+$  wherein M is a metal such as Li, Na or K e.g.  $-S^-\text{Na}^+$ , and the other substituents have the same meaning as defined in claim 7.




5

**17. A compound of the formula (III) and salts and solvates thereof**




10 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are defined as in claim 7; and

$Z$  represent the structural moiety resulting from the reaction between the steroidal carboxylic acid of formula (II) and a coupling agent (preferably EDC), followed by a coupling enhancer selected from the group consisting of the compounds of formulas (D); (E); (F); and (G):




15



wherein  $R_{11}$  and  $R_{12}$  independently represent a hydrogen atom or a cyano group;  $R_{13}$  represent a hydrogen atom or a methyl group; and  $R_{14}$  represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate [ie. the group  $-S(=O)(=O)\text{-O}^-\text{Na}^+$ ],

20

6



X = H, F, Cl, Br and Y = CH, N, O, S

with the proviso that:

5 when the coupling enhancer is a compound of formula (F), X can not represent H when Y  
represents CH;  
When the coupling enhancer is a compound of formula (D), R<sub>11</sub> and R<sub>12</sub> can not both represent  
H when R<sub>1</sub> in formula III represents OH; and  
when the coupling enhancer is a compound of formula (E), R<sub>14</sub> can not represent H when R<sub>1</sub> in  
10 formula III represents H;


and with the further proviso that

succinimidyl-9 $\alpha$ -fluoro-11 $\beta$ ,17 $\alpha$ -dihydroxy-16 $\alpha$ -methyl-3-oxoandrosta-1,4-diene-17 $\beta$ -carboxylate;

15 17 $\alpha$ -hydroxy-4-androsten-3-one-17 $\beta$ -carboxylic acid N-hydroxysuccinimide ester; N-hydroxysuccinimidyl-9-fluoro-16 $\alpha$ -methyl-11 $\beta$ ,17-dihydroxy-3-oxo-1,4-androstadiene-17 $\beta$ -carboxyester; N-hydroxysuccinimide ester of dexamethasone-17 $\beta$ -carboxylic acid; and  
1-[ $(9\alpha$ -fluoro-11 $\beta$ -hydroxy-16 $\beta$ -methyl-3-oxo-17 $\alpha$ -propionyloxy]androsta-1,4-dien-17 $\beta$ -yl]carbonyl]imidazole are disclosed.

18. The compound of claim 17, wherein at least one of R<sub>11</sub> and R<sub>12</sub> is a cyano group (C≡N), and/or R<sub>13</sub> is a hydrogen atom, and/or formula (D) is NMI (N-methylimidazole) or DCI (4,5-dicyano-imidazole), and/or formula (E) is NHS (N-hydroxysuccinimide) or sulfo-NHS (N-25 hydroxysulfosuccinimide).


**19. The compound having the formula:**



in which the substituents have the same meaning as defined in claim 17, and salts and solvates thereof, with the proviso that R14 can not represent H when R1 represents H.

5

**20. A compound of the formula (VI) and salts and solvates thereof**



10 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are defined as in claim 7; and R<sub>a</sub> and R<sub>b</sub> are defined as in claim 1;  
with the proviso that 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide-6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ ,17 $\alpha$ -isopropylidenedioxy-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylate is disclaimed.

15 21. A composition comprising a compound as defined in any of claims 17-20.

22. Use of a compound of any of the claims 17-20 as an intermediate in a method for preparing a steroidal carbothioate or a steroidal carbothioic acid, such as in a method for preparing fluticasone propionate.

20

23. Use according to claim 22, in which the method comprises reaction with a nucleophilic agent comprising a sulfur atom and/or comprises reaction with an electrophilic agent.